To establish the edited neoantigens, we prolonged our earlier neoantigen high quality mannequin4,5 that quantifies the immunogenic options of a neoantigen to suggest that two competing outcomes decide whether or not a neoantigen is high-quality—whether or not the immune system acknowledges or tolerates a neoantigenic mutation (Fig. 3a). To estimate the probability the immune system… Continue reading Neoantigen quality predicts immunoediting in survivors of pancreatic cancer